ALZAMEND NEURO INC -,0001 Logo
US02262M3088

ALZAMEND NEURO INC -,0001

Ins Portfolio
Kostengünstig und breit gestreut in Europa investieren. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Kaufen
  2
Halten
  0
Verkaufen
  0

Scoring-Modelle

Dividenden-Strategie0 / 15
HGI-Strategie3 / 18
Levermann-Strategie-7 / 13
Powered byaktien.guide

News


  • Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

    ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has completed the final closing of its $5 million private placement. As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreement (the “Agreement”) with a sophisticated investor (the “Investor”), pursuant to which Alzamend agreed to sell to the Investor up to 500 shares of Series C Convertible Preferred Stock (the “Preferred Stock”) and warrants (the “Warrants”) to purchase shares of Alzamend's common stock for a total purchase price of up to $5 million, less a five percent (5%) discount (the “Financing”) in seven monthly tranche closings (a “Tranche Closing”), starting in April 2025, with the Investor having the ability, in its sole discretion, to purchase Preferred Stock prior to the dates set for each Tranche Closing.» Mehr auf globenewswire.com


  • Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

    Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced the dosing of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.» Mehr auf globenewswire.com


  • Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

    Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 19, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced the enrollment of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte ALZAMEND NEURO INC -,0001 einen Umsatz von 0,00 und ein Nettoeinkommen von 1,00 Mio
(EUR)Jan. 2025
YOY
Umsatz0,00-
Bruttoeinkommen0,00100,00%
Nettoeinkommen1,00 Mio59,31%
EBITDA989,18k59,63%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+2,01 Mio
Anzahl Aktien
800,95k
52 Wochen-Hoch/Tief
+115,72 - +2,35
DividendenNein
Beta
-0,28
KGV (PE Ratio)
3,84
KGWV (PEG Ratio)
0,07
KBV (PB Ratio)
+4,70
KUV (PS Ratio)
+30,94

Unternehmensprofil

Alzamend Neuro, Inc. ist ein biopharmazeutisches Unternehmen im frühen klinischen Stadium, das sich auf die Entwicklung verschiedener Produkte zur Behandlung von neurodegenerativen Erkrankungen und psychiatrischen Störungen konzentriert. Seine Pipeline umfasst AL001, eine ionische Kokristalltechnologie, die eine therapeutische Kombination aus Lithium, Prolin und Salicylat zur Behandlung von Alzheimer und anderen neurodegenerativen Erkrankungen sowie psychiatrischen Störungen liefert, und AL002, eine Methode, bei der eine durch ein mutiertes Peptid sensibilisierte Zelle als zellbasierter therapeutischer Impfstoff verwendet wird, um die Fähigkeit des immunologischen Systems eines Patienten zur Bekämpfung von Alzheimer wiederherzustellen. Das Unternehmen wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in Atlanta, Georgia.

Name
ALZAMEND NEURO INC -,0001
CEO
Stephan Jackman
SitzAtlanta, ga
USA
Website
Industrie
Chemikalien
Börsengang
Mitarbeiter4

Ticker Symbole

BörseSymbol
NASDAQ
ALZN
Frankfurt
9ZT0.F
Hamburg
9ZT0.HM
München
9ZT0.MU
🍪

Parqet nutzt Cookies.Erfahre Mehr